Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Share Class Description:
WBO:EWLS: Ordinary SharesTotal Employee Number:
16,000Compare
Compare
Traded in other countries / regions
EW.USAEW.MexicoEWL.GermanyE1WL34.BrazilEWLS.Austria1EW.ItalyEW.Switzerland0REN.UK IPO Date
2019-10-25Description
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.22 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.45 | |||||
Interest Coverage | 85.34 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 13.25 | |||||
Beneish M-Score | -2.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.1 | |||||
3-Year EBITDA Growth Rate | -2.7 | |||||
3-Year EPS without NRI Growth Rate | 1.1 | |||||
3-Year FCF Growth Rate | 14.3 | |||||
3-Year Book Growth Rate | 23.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.29 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.32 | |||||
9-Day RSI | 75.87 | |||||
14-Day RSI | 70.44 | |||||
3-1 Month Momentum % | 3.78 | |||||
6-1 Month Momentum % | 2.12 | |||||
12-1 Month Momentum % | 12.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.42 | |||||
Quick Ratio | 3.63 | |||||
Cash Ratio | 2.61 | |||||
Days Inventory | 295.19 | |||||
Days Sales Outstanding | 40.47 | |||||
Days Payable | 47.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 2.01 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.87 | |||||
Operating Margin % | 27.62 | |||||
Net Margin % | 17.34 | |||||
EBITDA Margin % | 24.73 | |||||
FCF Margin % | 17.21 | |||||
OCF Margin % | 21.47 | |||||
ROE % | 10.6 | |||||
ROA % | 8.18 | |||||
ROIC % | 17.12 | |||||
3-Year ROIIC % | 0.88 | |||||
ROC (Joel Greenblatt) % | 52.6 | |||||
ROCE % | 11.81 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 48.03 | |||||
Forward PE Ratio | 30.97 | |||||
PE Ratio without NRI | 33.62 | |||||
Shiller PE Ratio | 35.73 | |||||
Price-to-Owner-Earnings | 71.03 | |||||
PEG Ratio | 6 | |||||
PS Ratio | 8.41 | |||||
PB Ratio | 5.07 | |||||
Price-to-Tangible-Book | 7.19 | |||||
Price-to-Free-Cash-Flow | 48.73 | |||||
Price-to-Operating-Cash-Flow | 39.06 | |||||
EV-to-EBIT | 35.26 | |||||
EV-to-Forward-EBIT | 30.19 | |||||
EV-to-EBITDA | 31.62 | |||||
EV-to-Forward-EBITDA | 25.07 | |||||
EV-to-Revenue | 7.82 | |||||
EV-to-Forward-Revenue | 7.32 | |||||
EV-to-FCF | 45.25 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Projected-FCF | 2.86 | |||||
Price-to-DCF (Earnings Based) | 1.84 | |||||
Price-to-DCF (FCF Based) | 4.38 | |||||
Price-to-Median-PS-Value | 0.88 | |||||
Price-to-Graham-Number | 3.28 | |||||
| Price-to-Net-Current-Asset-Value | 16.18 | |||||
| Price-to-Net-Cash | 77.46 | |||||
Earnings Yield (Greenblatt) % | 2.84 | |||||
FCF Yield % | 2.08 | |||||
Forward Rate of Return (Yacktman) % | 5.95 |
Edwards Lifesciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edwards Lifesciences Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 17:00 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 124 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 17:00 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 26 days | ||
| Guidance call for 2026 | 2026-05-12 15:40 | 65.18 (-3.98%) | ||
| General meeting for 2026 | 2026-05-07 10:00 | 70.52 (-0.40%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 17:00 | 69.14 (+1.29%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 69.14 (+1.29%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 10:00 | 73.32 (+0.78%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 10:00 | 72.07 (+3.97%) |
Show
Entries
Press Release
Articles on Edwards Lifesciences Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers